KALV Dec 2024 10.000 call
| Previous Close | 3.6500 |
| Open | 3.6500 |
| Bid | 1.7000 |
| Ask | 4.2000 |
| Strike | 10.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 3.6500 - 3.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
Business WireKalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
CAMBRIDGE, Mass. & SALISBURY, England, June 27, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged 2 to 11 years across seven countries in North America, Europe and Asia. KONFIDENT-KID will collect safety, pharmacokinetic, and efficacy data for each
Business WireKalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England, June 18, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older.
Business WireKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
CAMBRIDGE, Mass. & SALISBURY, England, June 06, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024, as well as the Japanese subgroup from KONFIDENT at the 123rd Annual Meeting of the Japanese Dermatological Association (JDA) 2024. KONFIDENT is the first pivotal phase 3 trial to include Japanese sites
